Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...
Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...
GlobalData on MSN16d
FDA approves Amgen’s combo therapy for colorectal cancerAmgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA for treating KRAS G12C-mutated mCRC.
KRAS G12C mutations, present in approximately 13% of lung adenocarcinoma cases, are associated with limited responses to current KRAS G12C inhibitor treatments such as adagrasib and sotorasib, with ...
Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.
今日，加科思药业宣布，其自主研发的KRAS G12C抑制剂戈来雷塞（glecirasib，JAB-21822）注册性临床试验数据在《Nature Medicine》（影响因子58.7）发布 ...
Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...
Lumakras and Vectibix combination approved for KRAS G12C-mutated mCRC after specific chemotherapy regimens. CodeBreaK 300 trial showed improved progression-free survival with Lumakras/Vectibix ...
2025年，全球医药领域将迎来一系列重要趋势和突破性进展。在肿瘤学、肥胖症药物以及人工智能（AI）应用的推动下，药物创新的格局正在被重新塑造，医疗健康产业也将面临前所未有的机遇与挑战。近期，《自然》旗下的Nature Reviews Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback